Market for Chronic Pain Therapies $20B Through 2020

Decision Resources, a pharmaceutical and healthcare research and advisory firm, found therapies to treat chronic back pain and arthritis pain will continue to be the most profitable segments of the chronic pain drug market through 2020, according to a news release.

Advertisement

The overall market for chronic pain therapies is predicted to remain stable at approximately $20 billion. Chronic back pain and arthritis pain together account for nearly 57 percent of the overall chronic pain drug market in 2010. The report also found pain physicians are skeptical the government-mandated Risk Evaluation and Mitigation Strategy programs will change physician prescribing habits.

Related Articles on Pain Management:
Dr. Andrew C. Charles Named First Luskin Chair in Migraine and Headache Studies at UCLA
DSM Collaborates with AdeTherapeutics to Develop Pain Management and Scar
Reduction Product for Spine Surgeries

Neuros Medical Receives Approval for Pilot Study of Electrical Nerve Block Technology

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

  • As the ASC industry continues to grow alongside new waves of surgical innovation, patient preferences and shifts to value-based care,…

  • A Pleasant View, Utah-based physician has been indicted on charges of obtaining unapproved drugs from China and selling them to…

  • From payer obstacles to operational pressures, five ASC leaders discuss the biggest frictions they’re facing. Note: Responses were lightly edited.…

Advertisement

Comments are closed.